All > Multiple Myeloma

Cilta-cel for Multiple Myeloma

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
Multiple MyelomaCilta-cel - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will follow patients who have received cilta-cel to see if there are any delayed adverse events.

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Similar Trials

1
GSK adoptive cell therapy
1
Ascorbate
1
CT053

Study Objectives

7 Primary · 6 Secondary · Reporting Duration: Up to 15 years

Up to 15 years
Investigator's Response Assessment of Long Term Follow-up on Chimeric Antigen Receptor T-cell (CAR-T) Therapy Based on Local Lab Assessments
Number of Participants with Chimeric Antigen Receptor (CAR) Transgene Level Greater Than (>) Lower Limit of Quantitation (LLOQ) in Peripheral Blood Cells
Number of Participants with Measurable Replication Competent Lentivirus (RCL) in Peripheral Blood
Number of Participants with New Incidence of Grade >= 3 Infection
Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder
Number of Participants with New Incidence of Grade Greater than or Equal to (>=) 3 Hematologic Disorder Including Hypogammaglobulinemia
Number of Participants with New Incidence or Exacerbation of a Pre-existing Neurologic Disorder
Number of Participants with New Incidence or Exacerbation of a Pre-existing Rheumatologic or Other Autoimmune Disorder
Number of Participants with New Malignancies and Recurrence of Pre-existing Malignancy
Number of Participants with Serious Adverse Events (SAEs)
Overall Survival (OS)
Pattern of Lentiviral Vector Integration Sites
Pattern of Vector Integration Sites

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
GSK adoptive cell therapy
1
Ascorbate
1
CT053

Trial Design

1 Treatment Group

Cilta-cel
1 of 1

Experimental Treatment

228 Total Participants · 1 Treatment Group

Primary Treatment: Cilta-cel · No Placebo Group · Phase 4

Cilta-cel
Drug
Experimental Group · 1 Intervention: Cilta-cel · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 15 years

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
927 Previous Clinical Trials
6,346,981 Total Patients Enrolled
65 Trials studying Multiple Myeloma
17,372 Patients Enrolled for Multiple Myeloma
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
713 Previous Clinical Trials
3,919,966 Total Patients Enrolled
47 Trials studying Multiple Myeloma
12,466 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
California100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
University of California, San Francisco100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top